NAVB Navidea Biopharmaceuticals Inc.

0.51
-0.02  -3%
Previous Close 0.53
Open 0.53
Price To Book 3.94
Market Cap 9,257,252
Shares 18,059,406
Volume 20,237
Short Ratio 1.53
Av. Daily Volume 509,141

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 2b trial is enrolling.
NAV3-31 (TC99m-tilmanocept)
Rheumatoid arthritis

Latest News

  1. Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMT
  2. Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results
  3. Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
  4. Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results
  5. Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock
  6. Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT
  7. Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study
  8. Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock
  9. Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock
  10. Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property
  11. Navidea: 1Q Earnings Snapshot
  12. Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results
  13. Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
  14. Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)
  15. Navidea Biopharmaceuticals Announces Reverse Stock Split
  16. Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates
  17. Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
  18. Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates
  19. Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT
  20. Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results